Navigation Links
The Systemic Lupus Erythematosus Market Will Grow Dramatically Over the Next Decade, Increasing from Approximately $900 Million in 2012 to $4 Billion in 2022
Date:10/30/2013

BURLINGTON, Mass., Oct. 30, 2013 /PRNewswire/ --  Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the systemic lupus erythematosus (SLE) market will grow dramatically over the next decade from approximately $900 million in 2012 to $4 billion in 2022 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The Pharmacor advisory service entitled Systemic Lupus Erythematosus finds that Benlysta, the first approved biologic for the disease, will be the primary driver of market growth throughout the forecast period with sales in 2022 of $1.1 billion. However, physician perceptions of Benlysta's modest efficacy, slow onset to action and restrictive label—which does not include patients with severe, active renal and central nervous system disease—leave opportunity for emerging agents with better efficacy profiles and acceptable safety to gain market share. In the B-cell modulator class alone, the anticipated entry of UCB's epratuzumab, Eli Lilly's tabalumab and Anthera Pharmaceuticals' blisibimod will drive sales of $1.1 billion by 2022, accounting for almost 30 percent of total SLE sales. Though concerns regarding safety will initially limit their uptake, as physicians gain experience towards the end of our forecast period, these new agents may see use ahead of Benlysta. As a class, the B-cell modulators will account for 65 percent of total market sales in 2022.

The report also finds that the uptake of Bristol-Myers Squibb's Orencia for the treatment of lupus nephritis, beginning in 2018, will be a significant driver of SLE market growth. Orencia's patient share in 2022 will be modest; however, the anticipated high price of the 30 mg/kg dose being tested in Phase III trials will drive its sales to account for approximately 19 percent of total SLE sales in 2022.

"Benlysta has received a lukewarm reception to the SLE market owing primarily to physician perceptions of its modest efficacy, slow onset to action and inability to be used in the high unmet need population of patients with severe, life-threatening organ involvement," said Decision Resources Analyst Laura Croal, Ph.D. "Owing to its high price in a largely generic market, Benlysta will lead market sales in 2022 on the strengths of its excellent safety profile, demonstrated efficacy in pivotal trials and first-to-market advantage. However, the drug will be vulnerable to emerging agents with acceptable safety profiles that demonstrate improvements in these key perceived weaknesses."

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. In the Psoriasis Drug Market, Continued Uptake of Janssens Stelara and the Launch of Emerging Systemic Therapies Will Drive Sales Growth to Nearly $9.2 Billion in 2022
2. Rheumatologists in the EU5 Give the Highest Satisfaction and Performance Ratings to Rituxan and Benlysta for the Treatment of Systemic Lupus Erythematosus (SLE)
3. Indias Largest Generic Drugmaker Ranbaxy Pays $500 Million to Settle Systemic Generic Drug Manufacturing Fraud
4. Anthera Announces Data from the Phase 2b PEARL-SC Study Will Be Presented at the 10th International Congress on Systemic Lupus Erythematosus
5. New Findings Offer Systemic Solutions to Address Non-communicable Diseases (NCDs) in Low- and Middle-income Countries
6. Anthera Announces the Advancement of Blisibimod into Phase 3 Development for Patients with Systemic Lupus Erythematosus (SLE)
7. New Research Available on the Multi-Billion Dollar Transmucosal Drug Delivery and Systemic Nasal Sprays Markets
8. New ALR-LRI Collaboration to Accelerate New Treatments for Lupus
9. Lupus Research Institute Hosts First International Conference to Advance New Treatments for Lupus Nephritis
10. Lupus Foundation of Florida Applauds Support for Biosimilars Legislation
11. For the Treatment of Lupus, the Emerging Therapies Epratuzumab and Lupuzor Have the Potential to Offer Improvements Over IV Belimumab in Reducing Disease Activity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016 Research and Markets has ... Companion Diagnostic Tests" report to their offering. ... Diagnostics The World Market for Companion Diagnostics ... diagnostics. Market analysis in the report includes the following: ... Vitro Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
(Date:6/24/2016)... , June 24, 2016 VolitionRx ... of Dr. Edward Futcher to the ... effective June 23, 2016.Dr. Futcher was also appointed ... Governance Committees.  As a non-executive member of the ... and strategic counsel to VolitionRx in connection with ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... ... "FCPX editors can now reveal their media with growing colorful split screen ... - CEO of Pixel Film Studios. , ProSlice Color brings the split screens ... reveal the media of their split screens with growing colorful panels. , ProSlice Color ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... payment industry today announced its strategic partnership with Connance, a healthcare industry ... The two companies’ proven, proprietary technology combine to provide health systems, hospitals ...
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their ... Eyeglasses . , Millions of individuals in the United States and Canada wear eyeglasses. ... way to both correct vision and make a fashion statement. Even celebrities use glasses ...
(Date:6/26/2016)... Creek, Michigan (PRWEB) , ... June 26, 2016 , ... ... joined as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in ... in honor of the city’s history as home to some of the world’s leading ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned by ... to enhance the health of felines. The formula is all-natural and is made from ... the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract ...
Breaking Medicine News(10 mins):